← Human Trials & Peer-Reviewed Studies
The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome.
Plain-language guide to PMID 8964866 (1996): multicenter controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 27 subjects.
Key Facts
- PMID
- 8964866
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 1996
- Study type
- Controlled Clinical Trial
- Authors
- Cotterill AM et al. (11 authors)
- DOI
- 10.1210/jcem.81.6.8964866
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.
Entry criteria were: NS confirmed by single observer, height SD score less than -2(UK Height Standards 1990), prepubertal, and normal maximal left ventricular (LV) wall thickness less than 1 cm by 2-dimensional echocardiography.
Measurements of maximal LV wall thickness were taken at 0 and 12 months.
Who Took Part
The study group was 27 subjects.
The age groups tagged for this paper are young children, children and teenagers, both men and women.
Thirty subjects were recruited (19 males and 11 females), aged 8.9 +/- 0.5 yr (range, 4.8-13.7 yr).
How the Study Was Run
In design terms this was a multicenter study.
Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.
What Was Measured
Entry criteria were: NS confirmed by single observer, height SD score less than -2(UK Height Standards 1990), prepubertal, and normal maximal left ventricular (LV) wall thickness less than 1 cm by 2-dimensional echocardiography.
Measurements of maximal LV wall thickness were taken at 0 and 12 months.
Topics PubMed links to this paper include Body Height, Body Mass Index, Child Development, Echocardiography, Growth Hormone, Heart Ventricles and Myocardium.
What This Means in Plain Language
The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 27 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1996 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.